Products On Sale

19 Item(s)

per page

Set Descending Direction
  1. AZD1480

    Catalog No. A10110
    Quick View
    JAK Inhibitor
    AZD1480 is a novel potent small JAK2 inhibitor with an IC50 of 0.26 nM. Learn More
  2. Curcumol

    Catalog No. A10247
    Quick View
    JAK2 inhibitor
    Curcumol induces apoptosis via caspases-independent mitochondrial pathway in human lung adenocarcinoma ASTC-a-1 cells. Learn More
  3. WP1066

    Catalog No. A11795
    Quick View
    JAK Inhibitor
    WP1066 is a novel JAK2 inhibitor and it suppresses proliferation and induces apoptosis in eythroid human cells carrying the JAK2 V617F mutation. Learn More
  4. Pyridone 6 (JAK Inhibitor I)

    Catalog No. A13457
    Quick View
    JAK inhibitor
    JAK Inhibitor I is a potent, reversible, cell-permeable, and ATP-competitive inhibitor of JAK1, JAK2, and JAK3. Learn More
  5. Cyt387 (Momelotinib)

    Catalog No. A10263
    Quick View
    JAK inhibitor
    CYT387 is an inhibitor of Janus kinases JAK1 and JAK2, acting as an ATP competitor with IC50 values of 11 and 18 nM, respectively. Learn More
  6. NVP-BSK805

    Catalog No. A11193
    Quick View
    JAK inhibitor

    NVP-BSK805 is a potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor that potently suppressed recombinant human erythropoietin-induced polycythemia and extramedullary erythropoiesis in mice and rats.

    Learn More
  7. CEP33779

    Catalog No. A12808
    Quick View
    JAK2 Inhibitor
    CEP33779 is a selective JAK2 inhibitor with IC50 of 1.8 nM. Learn More
  8. Filgotinib

    Catalog No. A14232
    Quick View
    JAK inhibitor
    Filgotinib is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Learn More
  9. AT9283

    Catalog No. A10095
    Quick View
    Aurora/JAK inhibitor
    AT9283 inhibits aurora kinase A and B and targets other tyrosine and serine/threonine kinases associated with myeloid cell proliferation. Learn More
  10. TG-101348 (Fedratinib, SAR302503)

    Catalog No. A11082
    Quick View
    JAK2 inhibitor
    TG-101348 is an orally bioavailable, ATP-competitive and selective inhibitor of Janus-associated kinase 2 with potential antineoplastic activity. Learn More
  11. BMS-911543

    Catalog No. A11241
    Quick View
    JAK inhibitor
    BMS-911543 is an orally available small molecule targeting a subset of Janus-associated kinase (JAK) with potential antineoplastic activity. Learn More
  12. TG-02 (SB1317)

    Catalog No. A11962
    Quick View
    FLT3 inhibitor
    TG-02 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Learn More
  13. KW-2449

    Catalog No. A10508
    Quick View
    FLT3/FGFR/Bcr-Abl/Aurora Inhibitor
    KW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase. Learn More
  14. Baricitinib (LY3009104)

    Catalog No. A11329
    Quick View
    JAK Inhibitor
    Baricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM). Learn More
  15. XL019

    Catalog No. A12394
    Quick View
    JAK2 inhibitor
    XL019 is an orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. Learn More
  16. AG-490

    Catalog No. A10047
    Quick View
    EGFR inhibitor
    AG 490 is a selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively). Also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src. Learn More
  17. AZ-960

    Catalog No. A10104
    Quick View
    JAK2inhibitor
    AZ-960 is a potent, selective and ATP competitive JAK2 inhibitor that inhibits JAK2 kinase with a Ki of 0.45 nM in vitro and induces growth arrest and apoptosis in adult T-cell leukemia (ATL) cell. Learn More
  18. Pacritinib (SB1518)

    Catalog No. A12694
    Quick View
    JAK2/FLT3 inhibitor
    Pacritinib, also known as SB1518, is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Pacritinib competes with JAK2 for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, and so caspase-dependent apoptosis. Learn More
  19. Cerdulatinib

    Catalog No. A14210
    Quick View
    multi-targeted tyrosine kinase inhibitor
    Cerdulatinib (PRT-062070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Learn More

19 Item(s)

per page

Set Descending Direction
Rewards